The EEA1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-mediated loss-of-function model targeting the EEA1 gene in a polyclonal HEK293T population. This pool of gene-disrupted cells is ideal for investigating early endosomal dynamics, endocytic trafficking, and signal termination without clonal isolation.
HEK293T is a human embryonic kidney epithelial line transformed with adenovirus 5 DNA and stably expressing SV40 large T antigen, enabling robust protein expression and viral production. Its genetic tractability and rapid growth make it a preferred host for CRISPR-based studies of cell signaling and trafficking.
EEA1 is a Rab5 effector that binds PI3P on early endosomes, driving homotypic fusion and tethering essential for cargo sorting and endosomal maturation. Through interactions with Rabaptin-5, hVPS34, SNX1, and Syntaxin 13, it facilitates the progression from Rab5-positive early endosomes to Rab7/LAMP1-positive late compartments. Upstream, PI3K-generated PI3P and Rab5 activate EEA1 recruitment, while loss of EEA1 disrupts receptor degradation, prolonging signaling from EGFR and other receptor tyrosine kinases.
In HEK293T cells, EEA1 knockout impairs early endosome fusion, leading to mistrafficking of internalized receptors and altered downstream signaling. This disruption is particularly relevant for studying how endosomal sorting defects contribute to cancer cell proliferation, autophagy misregulation, and neurodegenerative processes. The polyclonal nature offers a spectrum of editing efficiencies, enabling dose?Cresponse analyses of trafficking phenotypes.
Researchers can employ this model for immunofluorescence colocalization of endosomal markers, co-immunoprecipitation of EEA1 complexes, and live-cell imaging of endosome dynamics. Functional assays include fluorescent EGF/transferrin uptake to measure endocytosis, phospho-EGFR flow cytometry to quantify signaling termination, and Western blotting to confirm EEA1 depletion. Applications span drug delivery optimization and lysosomal storage disease research. For more information, contact Ascent Research.
